State Board of Administration of Florida Retirement System Increases Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

State Board of Administration of Florida Retirement System boosted its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) by 6.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,860 shares of the biotechnology company’s stock after purchasing an additional 1,660 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Aurinia Pharmaceuticals were worth $120,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of AUPH. AlphaCentric Advisors LLC raised its position in shares of Aurinia Pharmaceuticals by 121.0% during the 4th quarter. AlphaCentric Advisors LLC now owns 352,500 shares of the biotechnology company’s stock valued at $1,523,000 after buying an additional 193,000 shares in the last quarter. Fox Run Management L.L.C. raised its position in shares of Aurinia Pharmaceuticals by 24.7% during the 4th quarter. Fox Run Management L.L.C. now owns 34,281 shares of the biotechnology company’s stock valued at $148,000 after buying an additional 6,788 shares in the last quarter. Handelsbanken Fonder AB raised its position in shares of Aurinia Pharmaceuticals by 38.8% during the 4th quarter. Handelsbanken Fonder AB now owns 35,400 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 9,900 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Aurinia Pharmaceuticals by 8.6% during the 4th quarter. ProShare Advisors LLC now owns 29,014 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 2,290 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at about $46,000. Hedge funds and other institutional investors own 40.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on AUPH. Royal Bank of Canada upped their target price on shares of Aurinia Pharmaceuticals from $11.00 to $13.00 and gave the company an “outperform” rating in a research report on Tuesday, May 2nd. StockNews.com started coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, May 18th. They set a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Aurinia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Insider Activity

In other news, EVP Stephen P. Robertson sold 19,402 shares of the stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $8.94, for a total transaction of $173,453.88. Following the transaction, the executive vice president now directly owns 303,364 shares in the company, valued at $2,712,074.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Aurinia Pharmaceuticals news, EVP Stephen P. Robertson sold 19,402 shares of the firm’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $8.94, for a total value of $173,453.88. Following the completion of the sale, the executive vice president now directly owns 303,364 shares in the company, valued at $2,712,074.16. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Peter Greenleaf sold 32,750 shares of the firm’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $8.94, for a total transaction of $292,785.00. Following the completion of the sale, the chief executive officer now owns 982,968 shares of the company’s stock, valued at $8,787,733.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,453 shares of company stock worth $668,436. Corporate insiders own 3.70% of the company’s stock.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH stock opened at $11.31 on Wednesday. The company has a market capitalization of $1.62 billion, a P/E ratio of -16.88 and a beta of 1.18. The company’s 50-day simple moving average is $10.62 and its two-hundred day simple moving average is $8.13. Aurinia Pharmaceuticals Inc. has a one year low of $4.07 and a one year high of $13.41.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last issued its earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. The business had revenue of $34.41 million for the quarter, compared to the consensus estimate of $28.12 million. Aurinia Pharmaceuticals had a negative net margin of 65.90% and a negative return on equity of 23.56%. The company’s revenue for the quarter was up 59.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.27) EPS. On average, research analysts expect that Aurinia Pharmaceuticals Inc. will post -0.71 EPS for the current fiscal year.

About Aurinia Pharmaceuticals

(Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.